Exposure to industry promotional activity can lead to doctors recommending worse treatments for patients

This is my BMJ Rapid Response, of the 6th January 2018 to Mike Thompson, CEO of the ABPI. [Association of the British Pharmaceutical Industry] I share Mike Thompson’s disappointment in some aspects … Continue reading Exposure to industry promotional activity can lead to doctors recommending worse treatments for patients

Back in the driving seat: Industry

Historical backdrop (the last decade): UK Key Opinion Leaders argued robustly and consistently for an early approach to the diagnosis of dementia without articulating uncertainties, risks and necessary ethical aspects of person-centred … Continue reading Back in the driving seat: Industry

Psychopharmacology Committee (Strategy Meeting)

The June 2017 Agenda of the Royal College of Psychiatrists Psychopharmacology Committee confirms that a discussion on ‘involuntary addiction to prescription medications’ was scheduled. My view is that such discussions … Continue reading Psychopharmacology Committee (Strategy Meeting)

Psychiatry Without Borders

The International Congress of the Royal College of Psychiatrists took place in Edinburgh, the city of my birth, between the 26 – 29 June 2017. This International Congress was called … Continue reading Psychiatry Without Borders